Announced Date: 2023-12-11 (December 11, 2023)<\/p>\n\n\n\n
Asset Name: BL-B01D1 <\/p>\n\n\n\n
Licensor: SystImmune Inc., (a member of Sichuan Biokin Pharmaceutical Co., Ltd group., China)<\/p>\n\n\n\n
Licensee (Buyer): Bristol Myers Squibb\uff08BMS\uff09<\/p>\n\n\n\n
Asset Modality: BsADC\u00a0(bispecific antibody-drug conjugate), topoisomerase inhibitor-based<\/p>\n\n\n\n
Asset Target: \u00a0EGFRxHER3 (epidermal growth factor receptor, human epidermal growth factor receptor 3)<\/p>\n\n\n\n
<\/p>\n\n\n\n
\u00a0Potential Indication: \u00a0\u00a0<\/em><\/strong>lung and breast cancer, may expand into additional tumor types<\/p>\n\n\n\n Current Stage: global multi-center Phase 1 study\u00a0<\/p>\n\n\n\n <\/p>\n\n\n\n Scope of Authority:<\/p>\n\n\n\n \u00a0<\/em><\/strong>SystImmune and Bristol Myers Squibb to co-develop and co-commercialize BL-B01D1 in the United States; <\/p>\n\n\n\n SystImmune to retain exclusive rights in Mainland China and Bristol Myers Squibb to gain an exclusive license in the rest of the world.<\/p>\n\n\n\n <\/p>\n\n\n\n Deal Detail:<\/p>\n\n\n\n Upfront payment of\u00a0 $800 million,<\/p>\n\n\n\n Near-term payments up to $500 million,<\/p>\n\n\n\n Development, regulatory and sales performance milestones payments up to $\u00a0$7.1 billion,<\/p>\n\n\n\n Total up to $8.4 billion.<\/p>\n\n\n\n <\/p>\n\n\n\n Bristol Myers Squibb will receive a royalty on net sales in Mainland China,<\/p>\n\n\n\n SystImmune will receive a tiered royalty on net sales Outside the United States and Mainland China.<\/p>\n\n\n\n <\/p>\n\n\n\n Link:\u00a0<\/p>\n\n\n\n